Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Firdapse
Pharma
Eisai peddles US rights to epilepsy drug Fycompa to Catalyst
Eisai has inked a deal to sell U.S. rights of its epilepsy drug Fycompa to Florida-based Catalyst Pharmaceuticals for $160 million upfront.
Kevin Dunleavy
Dec 20, 2022 10:35am
Catalyst one-ups Jacobus, FDA in Firdapse exclusivity appeal
Oct 1, 2021 12:11pm
Catalyst sues FDA over 'capricious' approval for rival
Jun 12, 2019 10:45am
Catalyst's $375K Firdapse could get off-label competition
May 7, 2019 12:02pm
Patient group urges BIO to boot Catalyst over $375K Firdapse price
Mar 7, 2019 10:20am
Sanders asks FDA to sanction unapproved copies of $375K Firdapse
Feb 28, 2019 11:38am